M&A Deal Summary

Otsuka Pharmaceutical Acquires iBio - Preclinical PD-1 Agonist Antibody Program

On February 25, 2024, Otsuka Pharmaceutical acquired life science company iBio - Preclinical PD-1 Agonist Antibody Program from iBio for 53M USD

Acquisition Highlights
  • This is Otsuka Pharmaceutical’s 4th transaction in the Life Science sector.
  • This is Otsuka Pharmaceutical’s 6th largest (disclosed) transaction.
  • This is Otsuka Pharmaceutical’s 6th transaction in the United States.
  • This is Otsuka Pharmaceutical’s 1st transaction in Texas.

M&A Deal Summary
Date 2024-02-25
Target iBio - Preclinical PD-1 Agonist Antibody Program
Sector Life Science
Buyer(s) Otsuka Pharmaceutical
Sellers(s) iBio
Deal Type Divestiture
Deal Value 53M USD

Target

iBio - Preclinical PD-1 Agonist Antibody Program

Bryan, Texas, United States
iBio - Preclinical PD-1 Agonist Antibody Program is a pivotal checkpoint in the immune system, acting as a type of off switch that helps keep the cells from attacking other cells in the body. iBio's Preclinical PD-1 Agonist Antibody Program is based in Bryan, Texas.

Search 193,724 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Otsuka Pharmaceutical

Tokyo, Japan

website

Category Company
Founded 2008
Sector Healthcare Services
Employees32,992
Revenue 1,498.3B JPY (2021)
DESCRIPTION

Otsuka Group is striving to cultivate a culture and a dynamic corporate climate reflecting our vision as a healthcare company. As such we are dedicated to achieving global sustainability, to our relationships with local communities and to the protection of the natural environment. Otsuka Holdings was founded in 2008 and is based in Tokyo, Japan.

DEAL STATS #
Overall 8 of 8
Sector (Life Science) 4 of 4
Type (Divestiture) 1 of 1
State (Texas) 1 of 1
Country (United States) 6 of 6
Year (2024) 1 of 1
Size (of disclosed) 6 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-07-11 Visterra

Waltham, Massachusetts, United States

Visterra, Inc. is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Visterra is based in Waltham, Massachusetts.

Buy $430M

Seller(S) 1

SELLER

iBio

Bryan, Texas, United States

website

Category Company
Sector Life Science
Employees49
Revenue 2M USD (2021)
DESCRIPTION

iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of hard-to-target subdominant epitopes along with its sustainable, plant-based protein expression capabilities for cGMP manufacturing. iBio is based in Bryan, Texas.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Texas) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-09-21 RubrYc

San Carlos, California, United States

RubrYc is a biotechnology company that integrates chemistry and computation to discover and develop antibody-based drugs with unprecedented epitope selectivity. RubrYc was founded in 2017 and is based in San Carlos, California.

Buy -
Mergr

Product

Company

Legal